LLY compared with URGN: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

URGNUroGen Pharma Ltd.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

URGNUroGen Pharma Ltd.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

URGN

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±14.0%▼−16.45%×1.17

Q2 FY26±16.0%▲+16.31%×1.02

= impliedLLY realized, solidURGN realized, hatchedOne scale, both sides: full bar = 21%× = |realized| ÷ impliedSource: market data

May 6 '26

±16.0%

▲+10.16%

×0.64

Q1 FY26±20.4%▼−12.35%×0.60

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

URGNUroGen Pharma Ltd.

24.77▼−3.72%· post 24.38

ClosedNov 6 '26

Mkt cap$1.2BRevenue$89MQ3 FY26Revenue$110MFY25

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

URGNUroGen Pharma Ltd.

1,360.90▼−0.28%post 1,358.90

Price

24.77▼−3.72%post 24.38

$1.2T

Mkt cap

$1.2B

Q3 FY26$24.4B

Revenue

$89MQ3 FY26

FY25$65.2B

Revenue

$110MFY25

LLY1,360.90▼−0.28%vsURGN24.77▼−3.72%ClosedNov 6 '26